C9 and amyotrophic lateral sclerosis: To investigate the pathological differences between C9‐ALS and controls (Figure 1), post‐mortem tissue from a deeply clinically phenotyped cohort (Table 1) was stained with antibodies commonly used in the neuropathological work‐up of ALS cases.